Exercise capacity in people with polycythemia vera
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how your body responds to exercise if you have polycythemia vera. It aims to find biological and physical factors that affect your ability to be active, which may help guide safe exercise recommendations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 69 years old.
- You have polycythemia vera with a confirmed JAK2 V617F mutation.
- You have been prescribed a cardiopulmonary exercise test (CPET) because you want to start regular physical activity.
- You are covered by a social security scheme.
- You do not have a history of heart disease or chronic lung conditions like asthma that could affect your exercise test.
- You have not had a major blood clot complication.
- Your body mass index (BMI) is 35 or lower.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with high red blood cell counts (erythrocytosis) who are seen at a blood specialty clinic. The goal is to track their health over time to learn more about this condition and how it affects patients.
This trial tests a combination of two drugs—gecacitinib (a JAK inhibitor) and pegylated interferon—to see if they work better together for people with polycythemia vera (PV), a blood cancer that causes too many red blood cells. The study is for patients who have not tried these specific treatments before and who have symptoms like high blood counts, weight loss, night sweats, or an enlarged spleen.
This study looks at how thick your blood is (blood viscosity) if you have polycythemia, a condition where your body makes too many red blood cells. It aims to understand the relationship between blood thickness and your red blood cell levels.
This trial studies proteins and red blood cell production in people with polycythemia (high red blood cell count) to understand its causes. It may help improve care for patients with this condition.
This study watches how a blood condition called essential thrombocythemia (ET) changes into another condition called polycythemia vera (PV) in people with a specific JAK2 mutation. It aims to learn more about these changes and what happens to patients over time.
This study asks doctors how they diagnose and treat polycythaemia vera (PV), a blood condition where the body makes too many red blood cells. Your answers will help improve care for future patients.
Hear when a new Polycythemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.